全文获取类型
收费全文 | 6706篇 |
免费 | 480篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 166篇 |
妇产科学 | 99篇 |
基础医学 | 793篇 |
口腔科学 | 329篇 |
临床医学 | 522篇 |
内科学 | 1658篇 |
皮肤病学 | 144篇 |
神经病学 | 642篇 |
特种医学 | 258篇 |
外科学 | 960篇 |
综合类 | 17篇 |
预防医学 | 254篇 |
眼科学 | 114篇 |
药学 | 541篇 |
中国医学 | 14篇 |
肿瘤学 | 625篇 |
出版年
2023年 | 63篇 |
2022年 | 59篇 |
2021年 | 285篇 |
2020年 | 175篇 |
2019年 | 245篇 |
2018年 | 276篇 |
2017年 | 200篇 |
2016年 | 265篇 |
2015年 | 295篇 |
2014年 | 335篇 |
2013年 | 428篇 |
2012年 | 571篇 |
2011年 | 563篇 |
2010年 | 308篇 |
2009年 | 261篇 |
2008年 | 437篇 |
2007年 | 413篇 |
2006年 | 412篇 |
2005年 | 367篇 |
2004年 | 329篇 |
2003年 | 225篇 |
2002年 | 216篇 |
2001年 | 34篇 |
2000年 | 27篇 |
1999年 | 40篇 |
1998年 | 28篇 |
1997年 | 19篇 |
1996年 | 15篇 |
1995年 | 25篇 |
1994年 | 22篇 |
1993年 | 18篇 |
1992年 | 32篇 |
1991年 | 24篇 |
1990年 | 18篇 |
1989年 | 26篇 |
1988年 | 23篇 |
1987年 | 16篇 |
1986年 | 16篇 |
1985年 | 21篇 |
1984年 | 18篇 |
1983年 | 14篇 |
1982年 | 6篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 9篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1975年 | 7篇 |
1974年 | 5篇 |
1972年 | 4篇 |
排序方式: 共有7238条查询结果,搜索用时 15 毫秒
1.
Merashli Mira Bucci Tommaso Pastori Daniele Pignatelli Pasquale Ames Paul R. J. 《Clinical rheumatology》2022,41(12):3769-3776
Clinical Rheumatology - To perform a systematic review and meta-analysis of studies reporting data on atherosclerosis and inflammatory markers in familial Mediterranean fever (FMF). EMBASE and... 相似文献
2.
3.
Lucena Rita de Melo-Carneiro Pedro Sampaio Aline Santos de Almeida Nadia Rossi Ponte Ana Marta Vieira de Brito Wanderley Daniele de Mattos Adriana Marques Robatto Ana Paola Argollo Nayara 《Journal of autism and developmental disorders》2022,52(9):4202-4203
Journal of Autism and Developmental Disorders - 相似文献
4.
Marinella Lauriola Arianna Pani Giovanbattista Ippoliti Andrea Mortara Stefano Milighetti Marjieh Mazen Gianluca Perseghin Daniele Pastori Paolo Grosso Francesco Scaglione 《CTS Clinical and Translational Science》2020,13(6):1071
Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection do exist. We performed a retrospective single‐center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID‐19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in‐hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan–Meier curve P < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035–1.079, P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479–3.246, P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171–0.412, P < 0.001) was inversely associated. In this study, we found a reduced in‐hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is spreading worldwide since December 2019 and still no proven effective therapy has been found. First therapy proposed to treat coronavirus disease 2019 (COVID‐19) has been the association of lopinavir‐ritonavir, a protease inhibitor approved for HIV infection. However, Cao et al. observed no benefit comparing lopinavir‐ritonavir treatment of hospitalized patients with severe COVID‐19, 1 and this treatment is currently not recommended. Currently, only remdesivir has been approved for COVID‐19 treatment, as it reduced recovery time by 4 days in 1,063 patients randomized to either remdesivir 200 mg loading dose followed by 100 mg daily or placebo for up to 10 days 2 with a similar rate of adverse events between the 2 groups. 3 However, no effect on in‐hospital mortality was found.Chloroquine and its derivative hydroxychloroquine (HCQ), based on few preclinical studies, have also been proposed as therapies for COVID‐19. A Chinese randomized trial in patients with mild disease showed a significantly shorter recovery time in the group treated with HCQ vs. the standard of care along with a radiological improvement. 4 Differently, a retrospective study performed in the United States Veterans Health Administration medical centers found an increased mortality associated with the treatment with HCQ. 5 Moreover, an observational study has shown no significant association between HCQ use and risk of intubation or death. 6 Furthermore, a recent randomized controlled trial has found no differences between patients treated with HCQ plus the standard of care vs. the standard of care alone in terms of virus elimination. 7 On the basis of a very small nonrandomized study, azithromycin has been proposed as possible treatment in association with HCQ. 8 Azithromycin, is an antibiotic belonging to the class of macrolides, with some proven efficacy in acute respiratory distress syndrome. 9 , 10 It is known to have immunomodulatory properties through the polarization of macrophages toward the reparative state 11 and the reduction in the production of pro‐inflammatory cytokines, such as IL‐8, IL‐6, TNF alpha, 12 and iNOS expression. 13 Recently, two large retrospective studies evaluating in‐hospital mortality associated with the use of the combination of HCQ and azithromycin (or another macrolide, such as clarithromycin), have shown no benefits. 14 Despite the lack of a proven clinical efficacy and some concerns regarding the possible QT prolongations caused by the association of HCQ and azithromycin, 15 given the low price and the wide availability, the association of these two drugs has become the most used treatment in patients with moderate‐severe COVID‐19.Because of the urgent need to find answers to the many questions posed by the fight to SARS‐CoV2 infection and some negative evidences regarding the use of HCQ, we here propose a retrospective observational study to assess the efficacy of the combination of HCQ plus azithromycin for hospitalized patients with medium‐severe COVID‐19. 相似文献
5.
6.
Larissa Daniele Machado Góes Patrícia Motta de Morais Paula Frassinetti Bessa Rebello Antônio Pedro Mendes Schettini 《Anais brasileiros de dermatologia》2022,97(2):231-235
Patients with lepromatous or borderline leprosy may present two types of vasculonecrotic reactions: Lucio’s phenomenon (LP) and necrotic erythema nodosum leprosum (nENL). These are serious conditions, which mostly lead to life-threatening infectious and thrombotic complications. The authors report the case of a patient with leprosy recurrence associated with an atypical type II reaction with LP characteristics on histopathology. 相似文献
7.
Ashton A. Connor Robert E. Denroche Gun Ho Jang Mathieu Lemire Amy Zhang Michelle Chan-Seng-Yue Gavin Wilson Robert C. Grant Daniele Merico Ilinca Lungu John M.S. Bartlett Dianne Chadwick Sheng-Ben Liang Jenna Eagles Faridah Mbabaali Jessica K. Miller Paul Krzyzanowski Heather Armstrong Steven Gallinger 《Cancer cell》2019,35(2):267-282.e7
8.
Umberto Cillo MD Alessandra Bertacco MD Elisa Fasolo Riccardo Carandina MD Alessandro Vitale MD Giacomo Zanus MD Enrico Gringeri MD Francesco D'Amico MD Domenico Bassi MD Daniele Neri MD Vincenzo Dadduzio MD Fabio Farinati MD Camillo Aliberti MD 《Journal of surgical oncology》2019,120(6):956-965
Background: Videolaparoscopic (VL) microwave ablation (MWA) is not included in most of the international guidelines as a therapeutic option for hepatocellular carcinoma (HCC). Aim of this study was to assess the safety of VL MWA in patients with HCC for whom resection or percutaneous ablation is unsuitable. Methods: A retrospective analysis was performed on a prospective database of patients with HCC treated with VL MWA at our institution from 2009 to 2016. Patient demographics, operational characteristics, and complications were recorded. Statistical analysis was performed to identify safety profile, overall survival and recurrence rate. Results: A total of 815 VL MWA were performed in 674 patients with a mean age of 64 years. Patients had a mean Model for End-stage Liver Disease score of 10 (±3); 32.8% were Child B, 44.1% Barcelona Clinic Liver Cancer B-C. Perioperative mortality was 0.4%. Overall morbidity was 30.8%, with Dindo-Clavien complications ≥3 in 2%. The median length of stay was 2 days. In 43.1% VL MWA was the first-line therapy. Overall 1-, 3-, and 5-year survival rates were 81.9%, 54.9%, and 35.9%. Conclusions: The present is the largest series of VL ablation and the bigger number of patients with HCC treated with MW reported nowadays. It confirms the safety of a minimally invasive procedure for patients with HCC when resection or percutaneous ablation is not feasible. 相似文献
9.
Giorgio Gandaglia Guillaume Ploussard Massimo Valerio Agostino Mattei Cristian Fiori Nicola Fossati Armando Stabile Jean-Baptiste Beauval Bernard Malavaud Mathieu Roumiguié Daniele Robesti Paolo Dell’Oglio Marco Moschini Stefania Zamboni Arnas Rakauskas Francesco De Cobelli Francesco Porpiglia Francesco Montorsi Alberto Briganti 《European urology》2019,75(3):506-514
Background
Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies.Objective
To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies.Design, setting, and participants
A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified.Outcome measurements and statistical analyses
Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated.Results and limitations
Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC).Conclusions
Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting.Patient summary
We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI. 相似文献10.
Fabio Frosio Federico Mocchegiani Grazia Conte Enrico Dalla Bona ANDrea Vecchi Daniele Nicolini Marco Vivarelli 《World journal of gastrointestinal surgery》2019,(6)
Cholangiocarcinoma(CCA) is a malignant tumor of the biliary system and includes, according to the anatomical classification, intra hepatic CCA(iCCA),hilar CCA(hCCA) and distal CCA(dCCA). Hilar CCA is the most challenging type in terms of diagnosis, treatment and prognosis. Surgery is the only treatment possibly providing long-term survival, but only few patients are considered resectable at the time of diagnosis. In fact, tumor's extension to segmentary or subsegmentary biliary ducts, along with large lymph node involvement or intrahepatic metastases, precludes the surgical approach. To achieve R0 margins is mandatory for the disease-free survival and overall survival. In case of unresectable locally advanced hCCA, radiochemotherapy(RCT) as neoadjuvant treatment demonstrated to be a therapeutic option before either hepatic resection or liver transplantation. Before liver surgery, RCT is believed to enhance the R0 margins rate. For patients meeting the Mayo Clinic criteria, RCT prior to orthotopic liver transplant(OLT) has proved to produce acceptable 5-years survivals. In this review, we analyze the current role of neoadjuvant RCT before resection as well as before OLT. 相似文献